NCT05395624View on ClinicalTrials.gov

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 2, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

May 1, 2026

Conditions
Amyotrophic Lateral Sclerosis (ALS)Parkinson Disease (PD)Alzheimer Disease (AD)Multiple Sclerosis (MS)
Interventions
DRUG

18F-OP-801

18F Hydroxyl Dendrimer

Trial Locations (3)

32224

RECRUITING

Mayo Clinic Jacksonville, Jacksonville

94107

RECRUITING

UCSF, San Francisco

94305

RECRUITING

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

Ashvattha Therapeutics, Inc.

INDUSTRY

NCT05395624 - Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers | Biotech Hunter | Biotech Hunter